CN111197022A - Voxel printing biological ink and preparation method thereof - Google Patents
Voxel printing biological ink and preparation method thereof Download PDFInfo
- Publication number
- CN111197022A CN111197022A CN202010101998.XA CN202010101998A CN111197022A CN 111197022 A CN111197022 A CN 111197022A CN 202010101998 A CN202010101998 A CN 202010101998A CN 111197022 A CN111197022 A CN 111197022A
- Authority
- CN
- China
- Prior art keywords
- chain
- long chain
- ultra
- extracellular matrix
- matrix material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000007639 printing Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 53
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 53
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 53
- 239000011159 matrix material Substances 0.000 claims abstract description 41
- 229920000642 polymer Polymers 0.000 claims abstract description 23
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 108010035532 Collagen Proteins 0.000 claims description 18
- 102000008186 Collagen Human genes 0.000 claims description 18
- 229920001436 collagen Polymers 0.000 claims description 18
- 230000000295 complement effect Effects 0.000 claims description 11
- 108010082117 matrigel Proteins 0.000 claims description 11
- 239000002657 fibrous material Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 239000003292 glue Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920000140 heteropolymer Polymers 0.000 claims description 3
- 229920001519 homopolymer Polymers 0.000 claims description 3
- 238000004804 winding Methods 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 10
- 238000004132 cross linking Methods 0.000 description 17
- 239000000976 ink Substances 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000011476 stem cell transplantation Methods 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000002020 noncytotoxic effect Effects 0.000 description 2
- 210000002220 organoid Anatomy 0.000 description 2
- 230000004537 potential cytotoxicity Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- 238000006596 Alder-ene reaction Methods 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
A voxel printing biological ink and a preparation method thereof are provided, the method comprises the following steps: premixing two ultra-long chain biocompatible molecules with an extracellular matrix material respectively to obtain two premixed components, and injecting the two premixed components into microdroplets to generate mixture microdroplets; the droplets are made to flow in the micro-fluidic pipeline, two ultra-long chain biocompatible molecules serving as cross-linking agent molecules and the extracellular matrix material and two ultra-long chain biocompatible molecules are fully mixed and wound under the circulation flow in the droplets, chain nodes are formed by interweaving, and the extracellular matrix material is locked in the wound ultra-long chain molecule chains to form an integral network. The voxel printing biological ink obtained by the invention has good biocompatibility, high designability, simple application and no harm to occluded cells.
Description
Technical Field
The invention relates to biotechnology, in particular to voxel printing biological ink and a preparation method thereof.
Background
Extracellular matrix (ECM) is a network structure composed of macromolecules such as proteins and polysaccharides secreted and distributed outside cells, and the main components are various materials such as proteins (e.g., collagen, elastin, etc.), non-collagenous glycoproteins, and proteoglycans (proteoglycan). ECM plays a supporting, protecting and nourishing role for tissue cells, and is also bound to cells through cell surface specific receptors, and is closely related to basic vital activities such as proliferation, differentiation, metabolism, recognition, adhesion and migration of cells. Bio-inks based on extracts (components) of the mammalian natural extracellular matrix, such as collagen or matrigel, are important foundations for stem cell transplantation, 3D organ printing and in vitro pathology model fabrication. The biological ink has the potential of remarkably improving the treatment efficiency of stem cells by being used as an implantation carrier to assist stem cell transplantation; both 3D organ printing and pathological organ model fabrication rely on biomaterials to provide structural retention and support stem cell survival. However, native ECM has the disadvantages of low mechanical strength and slow gelation, which limits its application as a voxel printing ink (e.g., gel cell soft spheres). The introduction of chemical crosslinking (including thermal crosslinking and photoreactive crosslinking, etc.) can promote gelation and enhance mechanical properties, but the crosslinking agent or crosslinking conditions are generally detrimental to the cells, while the rate of harmless thiol-ene reaction is low.
Disclosure of Invention
The invention mainly aims to overcome the technical defects and provide the voxel printing biological ink and the preparation method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a preparation method of voxel printing bio-ink comprises the following steps:
premixing a first ultra-long chain biocompatible molecule with an extracellular matrix material to obtain a first premixed component;
premixing the second ultra-long chain biocompatible molecule with an extracellular matrix material to obtain a second premixed component;
injecting the first premixed component and the second premixed component into droplets, resulting in mixture droplets;
and (2) driving the micro-droplets to flow in a micro-fluidic pipeline by using a micro-fluidic technology, fully mixing and winding the first and second ultra-long chain biocompatible molecules serving as cross-linking agent molecules with the extracellular matrix material and the first and second ultra-long chain biocompatible molecules under the circulation flow in the micro-droplets, interweaving to form chain nodes, and locking the extracellular matrix material in the wound ultra-long chain molecule chains to form an integral network.
Further:
injecting the first premixed component and the second premixed component separately into the droplets, or mixing the first premixed component and the second premixed component prior to injecting the droplets.
The first ultra-long chain biocompatible molecule is a DNA single chain, a macromolecular chain or a polypeptide chain, and the second ultra-long chain biocompatible molecule is a complementary chain of the DNA single chain, a homogeneous/heterogeneous macromolecular chain or a polypeptide chain which can generate chain reaction or acting force with the macromolecular chain or the polypeptide chain.
The chain nodes are formed by one or more of hydrogen bond complementation, heterogeneous charge attraction, covalent bonding, and physical entanglement.
The extracellular matrix material includes a protein fiber material including collagen and matrigel.
The ultra-long chain biocompatible molecules are crosslinked and solidified with extracellular matrix materials to generate soft spheres, or a plurality of soft spheres are fused into a strip glue after flowing and extruding.
A voxel printing biological ink comprises a first super-long chain biocompatible molecule, a second super-long chain biocompatible molecule and an extracellular matrix material, wherein the first super-long chain biocompatible molecule, the second super-long chain biocompatible molecule and the extracellular matrix material are fully mixed and wound as cross-linking agent molecules, the first super-long chain biocompatible molecule and the second super-long chain biocompatible molecule are interwoven to form chain nodes, and the extracellular matrix material is locked in the wound chain of the super-long chain molecules to form an integral network.
Further:
the first ultra-long chain biocompatible molecule is a DNA single chain, a macromolecular chain or a polypeptide chain, and the second ultra-long chain biocompatible molecule is a complementary chain of the DNA single chain, a homogeneous/heterogeneous macromolecular chain or a polypeptide chain which can generate chain reaction or acting force with the macromolecular chain or the polypeptide chain.
The chain nodes are formed by one or more of hydrogen bond complementation, heterogeneous charge attraction, covalent bonding, and physical entanglement.
The extracellular matrix material comprises a protein fiber material comprising collagen and matrigel; the ultra-long chain biocompatible molecules are crosslinked and solidified with extracellular matrix materials to generate soft spheres, or a plurality of soft spheres are fused into a strip glue after flowing and extruding.
The invention has the following beneficial effects:
the invention provides a voxel printing biological ink and a preparation method thereof, wherein two ultra-long chain biocompatible molecules are used as a non-cytotoxic cross-linking agent and are injected into microdrops together with ECM, a microfluidic flow dynamics field is utilized to enable the two ultra-long chain biocompatible molecules and ECM to be fully mixed and wound and the two ultra-long chain biocompatible molecules to be interwoven to form chain nodes, and the ECM is locked in the wound ultra-long chain molecule chains to form an integral network, so that the cross-linking of natural ECM such as protein fiber materials and the like is effectively promoted, the voxel printing ink is obtained, and the dependence on toxic or complex chemical reaction conditions required for cells is avoided. The crosslinking strategy in the invention is different from the traditional crosslinking reagent or crosslinking condition with potential cytotoxicity such as chemistry (such as crosslinking by using chemical crosslinking molecules and generating heat or photoreaction) or physical crosslinking (such as ultraviolet ray or gamma ray irradiation, dehydration crosslinking and the like), and the like. The cross-linked native ECM and its derived materials of the invention may better reduce the native matrix microenvironment of stem cells and the like compared to synthetic hydrogels. The application of the invention can greatly expand the application of natural biological materials in regeneration and transformation medicine, and is expected to promote the development and application of the fields of stem cell transplantation, organoid manufacture, 3D organ printing and the like.
Drawings
Fig. 1 is a schematic diagram of an internal flow cycle of a droplet flowing in a microfluidic channel according to an embodiment of the present invention.
FIG. 2 is a schematic diagram of the embodiment of the present invention in which the ultra-long chain molecules are mixed and interlaced by internal circulation of microdroplets to form "locked" nodes of the immobilized fibrous scaffold material (e.g., collagen and matrigel).
FIG. 3(a) is a schematic diagram showing the mechanical properties of collagen of the ultra-long chain molecule interweaving node "locked" solidified collagen-based soft spheres according to the embodiment of the present invention; FIG. 3(b) is a partial SEM image of a soft sphere; FIG. 3(c) is a global view of a soft sphere.
Fig. 4 is a representation of a matrix gum base soft sphere with "locked" solidification of the interwoven nodes of ultralong chain molecules in an embodiment of the invention.
FIG. 5 is two schematic views showing how several collagen-based soft spheres "locked" and solidified by the interweaving nodes of very long chain molecules are fused into a long-strand glue after flowing and extruding.
Detailed Description
The embodiments of the present invention will be described in detail below. It should be emphasized that the following description is merely exemplary in nature and is not intended to limit the scope of the invention or its application.
It will be understood that when an element is referred to as being "secured to" or "disposed on" another element, it can be directly on the other element or be indirectly on the other element. When an element is referred to as being "connected to" another element, it can be directly connected to the other element or be indirectly connected to the other element. In addition, the connection may be for either a fixed or coupled or communicating function.
It is to be understood that the terms "length," "width," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," and the like are used in an orientation or positional relationship indicated in the drawings for convenience in describing the embodiments of the present invention and to simplify the description, and are not intended to indicate or imply that the referenced device or element must have a particular orientation, be constructed in a particular orientation, and be in any way limiting of the present invention.
Fig. 1 is a schematic diagram of an internal flow cycle of a droplet flowing in a microfluidic channel according to an embodiment of the present invention. FIG. 2 is a schematic diagram of the formation of "locked" junctions of immobilized extracellular matrix materials (e.g., collagen and matrigel) by mixing and interlacing of ultralong-chain molecules through internal circulation of microdroplets in accordance with an embodiment of the present invention.
Referring to fig. 1 and 2, an embodiment of the present invention provides a method for preparing a voxel-printing bio-ink, including the following steps: premixing a first ultra-long chain biocompatible molecule 4 with an extracellular matrix material 6 to obtain a first premixed component; premixing a second ultra-long chain biocompatible molecule 5 with an extracellular matrix material 6 to obtain a second premixed component; wherein the first ultralong-chain biocompatible molecule 4 and the second ultralong-chain biocompatible molecule 5 are complementary cross-linker molecules; injecting the first premixed component and the second premixed component into microdroplets 1, resulting in mixture microdroplets; the droplets 1 are driven to flow in the microfluidic pipeline 2 by using a microfluidic flow dynamic field, and under the condition of circulating flow in the droplets 1 (see a circulating flow direction 3 in fig. 1), the first and second ultra-long chain biocompatible molecules 5 serving as cross-linking agent molecules and the extracellular matrix material 6, and the first and second ultra-long chain biocompatible molecules 4 and 5 are sufficiently mixed and wound to form chain nodes in an interweaving manner, so that the extracellular matrix material 6 is locked in the wound ultra-long chain molecule chains to form an integral network.
In some embodiments, the first and second premixed components may be injected into the microdroplets 1 separately to produce the mixture microdroplets 1. In other embodiments, the first premixed component and the second premixed component may be mixed prior to injection into the droplets 1.
In some embodiments, the first ultralong-chain biocompatible molecule 4 is a single DNA strand, a polymer strand, or a polypeptide chain, and the second ultralong-chain biocompatible molecule 5 is a complementary strand of the single DNA strand, a homo/hetero polymer strand, or a polypeptide chain that can produce an interchain reaction or force with the polymer strand or the polypeptide chain.
In some embodiments, the chain nodes 7 are formed by one or more of hydrogen bond complementation, heterogeneous charge attraction, covalent bonding, physical entanglement.
The extracellular matrix material 6 comprises a protein fibrous material comprising collagen and matrigel.
As shown in fig. 3(c), fig. 4 and fig. 5, the ultra-long chain biocompatible molecule crosslinks and solidifies the extracellular matrix material 6 to form soft spheres, or further fuses a plurality of the soft spheres into a growing gelatin after flowing and extruding.
Referring to fig. 2 to 5, a bio-ink for voxel printing includes a first ultra-long chain biocompatible molecule 4, a second ultra-long chain biocompatible molecule 5 and an extracellular matrix material 6, wherein the first ultra-long chain biocompatible molecule 4, the second ultra-long chain biocompatible molecule 5 and the extracellular matrix material 6, and the first ultra-long chain biocompatible molecule 4 and the second ultra-long chain biocompatible molecule 5 are mixed and wound together as cross-linker molecules, and are interwoven to form chain nodes 7, so that the extracellular matrix material 6 is locked in the wound ultra-long chain molecule chains to form an integral network.
The first ultra-long chain biocompatible molecule 4 and the second ultra-long chain biocompatible molecule 5 are complementary cross-linking agent molecules, the first ultra-long chain biocompatible molecule 4 is a single DNA chain, a macromolecular chain or a polypeptide chain, and the second ultra-long chain biocompatible molecule 5 is a complementary chain of the single DNA chain, a homogeneous/heterogeneous macromolecular chain or a polypeptide chain which can generate an inter-chain reaction or acting force with the macromolecular chain or the polypeptide chain. The chain nodes 7 are formed by one or more of hydrogen bond complementation, heterogeneous charge attraction, covalent bonding, and physical entanglement.
Wherein the extracellular matrix material 6 comprises a protein fiber material comprising collagen and matrigel; the ultra-long chain biocompatible molecules are crosslinked and solidified with extracellular matrix materials to generate soft spheres, or a plurality of soft spheres are fused into a strip glue after flowing and extruding.
In the embodiment of the invention, extracellular matrix extraction component materials such as collagen, matrigel and the like are used to obtain a fiber soft scaffold material, the fiber soft scaffold material is mixed with two ultra-long chain biocompatible molecules in micro-droplets, and the cross-linking is realized by micro-scale fluid flow regulation/drive. In the cross-linking agent, one kind of ultra-long chain biocompatible molecule (such as a DNA single chain (ultra-long single-chain ssDNA), a polymer chain, a polypeptide chain and the like) is premixed with the fiber material, intermolecular forces (such as electrostatic force, hydrogen bonding effect or covalent bonding effect and the like) exist between the cross-linking agent molecule and the fiber, and the other kind of ultra-long chain biocompatible molecule (such as a complementary chain of the DNA single chain, the same kind of polymer chain (or different kind of polypeptide chain) which can generate the interchain reaction or the acting force with the polymer chain (or polypeptide chain) and the like) is also premixed with the fiber material. The two pre-mixed components can be injected into the droplet-microfluidic to produce a mixture droplet, either separately or after mixing. As shown in fig. 1 and fig. 2, the micro-droplets are driven to flow in the micro-fluidic pipeline by using a micro-fluidic flow dynamic field, the mixed liquid promotes the molecules of the cross-linking agent to be fully mixed and wound with the fibers under the circulation flow in the micro-droplets, and the molecules of the complementary cross-linking agent are interwoven to form chain nodes to lock the fibers in the ultra-long chain winding to form an integral network. Junction formation may be hydrogen bond complementation, heterogeneous charge attraction, covalent bonding, or physical entanglement.
Exemplary results of crosslinking collagen and matrigel by ultralong-chain biocompatible molecules to form soft structure spheres and elongated gel are shown in fig. 3(a) -5. FIG. 3(a) shows the collagen mechanical properties of the ultra-long chain molecule interweaving nodes "locked" into the solidified collagen-based soft spheres of the present invention; FIG. 3(b) is a partial SEM image of a soft sphere; FIG. 3(c) is a global view of a soft sphere. Fig. 4 shows an embodiment of the invention in which the interwoven nodes of ultralong chain molecules "lock" the solidified matrix gum-based softspheres. FIG. 5 shows two examples of how several collagen-based soft spheres "locked" and solidified by the interweaving nodes of very long chain molecules are fused into a long-strand glue after flowing and extruding.
In the embodiment of the invention, two ultra-long chain biocompatible molecules are used as a non-cytotoxic cross-linking agent to be injected into a microdrop together with ECM, and a microfluidic flow dynamics field is utilized to ensure that the two ultra-long chain biocompatible molecules are fully mixed and wound with the ECM and the two ultra-long chain biocompatible molecules are mutually interwoven to form chain nodes, and the ECM is locked in the wound ultra-long chain molecule chain to form an integral network, so that the cross-linking of natural ECM such as protein fiber materials and the like is effectively promoted, the voxel printing ink is obtained, and the condition of depending on toxic or complex chemical reaction to cells is avoided. The crosslinking strategy in the invention is different from the traditional crosslinking reagent or crosslinking condition with potential cytotoxicity such as chemistry (such as crosslinking by using chemical crosslinking molecules and generating heat or photoreaction) or physical crosslinking (such as ultraviolet ray or gamma ray irradiation, dehydration crosslinking and the like), and the like. The cross-linked native ECM and its derived materials of the invention may better reduce the native matrix microenvironment of stem cells and the like compared to synthetic hydrogels. The application of the invention can greatly expand the application of natural biological materials in regeneration and transformation medicine, and is expected to promote the development and application of the fields of stem cell transplantation, organoid manufacture, 3D organ printing and the like.
The background of the present invention may contain background information related to the problem or environment of the present invention and does not necessarily describe the prior art. Accordingly, the inclusion in the background section is not an admission of prior art by the applicant.
The foregoing is a more detailed description of the invention in connection with specific/preferred embodiments and is not intended to limit the practice of the invention to those descriptions. It will be apparent to those skilled in the art that various substitutions and modifications can be made to the described embodiments without departing from the spirit of the invention, and these substitutions and modifications should be considered to fall within the scope of the invention. In the description herein, references to the description of the term "one embodiment," "some embodiments," "preferred embodiments," "an example," "a specific example," or "some examples" or the like are intended to mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Various embodiments or examples and features of various embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction. Although embodiments of the present invention and their advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the scope of the claims.
Claims (10)
1. A preparation method of voxel printing biological ink is characterized by comprising the following steps:
premixing a first ultra-long chain biocompatible molecule with an extracellular matrix material to obtain a first premixed component;
premixing the second ultra-long chain biocompatible molecule with an extracellular matrix material to obtain a second premixed component;
injecting the first premixed component and the second premixed component into droplets, resulting in mixture droplets;
and (2) driving the micro-droplets to flow in a micro-fluidic pipeline by using a micro-fluidic technology, fully mixing and winding the first and second ultra-long chain biocompatible molecules serving as cross-linking agent molecules with the extracellular matrix material and the first and second ultra-long chain biocompatible molecules under the circulation flow in the micro-droplets, interweaving to form chain nodes, and locking the extracellular matrix material in the wound ultra-long chain molecule chains to form an integral network.
2. The method of making a voxel-printing bio-ink of claim 1, wherein the first pre-mixed component and the second pre-mixed component are separately injected into the droplets or the first pre-mixed component and the second pre-mixed component are mixed and then injected into the droplets.
3. The method of any one of claims 1-2, wherein the first ultralong-chain biocompatible molecule is a single DNA chain, a polymer chain, or a polypeptide chain, and the second ultralong-chain biocompatible molecule is a complementary chain of the single DNA chain, a homo/hetero polymer chain, or a polypeptide chain that can react or act with the polymer chain or the polypeptide chain.
4. The method of producing a voxel printing bio-ink according to any of claims 1 to 3, wherein the chain junctions are formed by one or more of hydrogen bond complementation, heterogeneous charge attraction, covalent bonding, physical entanglement.
5. The method of preparing a voxel printing bio-ink according to any of the claims 1 to 4, wherein the extracellular matrix material comprises a protein fiber material comprising collagen and matrigel.
6. The method for preparing a bio-ink for voxel printing according to any one of claims 1 to 5, wherein the ultra-long chain biocompatible molecule is cross-linked and solidified to form a soft sphere from an extracellular matrix material, or a plurality of the soft spheres are further fused into a long stripe glue after being flow extruded.
7. A voxel printing bio-ink is characterized by comprising a first super-long chain biocompatible molecule, a second super-long chain biocompatible molecule and an extracellular matrix material, wherein the first super-long chain biocompatible molecule, the second super-long chain biocompatible molecule and the extracellular matrix material and the first super-long chain biocompatible molecule and the second super-long chain biocompatible molecule which are used as cross-linking agent molecules are fully mixed and wound to form chain nodes in an interweaving mode, and the extracellular matrix material is locked in the wound super-long chain molecule chains to form an integral network.
8. The method of claim 7, wherein the first ultralong-chain biocompatible molecule is a single DNA chain, a polymer chain, or a polypeptide chain, and the second ultralong-chain biocompatible molecule is a complementary chain of the single DNA chain, a homo/hetero polymer chain or a polypeptide chain that can react or act with the polymer chain or the polypeptide chain.
9. The method of producing a voxel printing bio-ink according to any of claims 7 to 8, wherein the chain junctions are formed by one or more of hydrogen bond complementary action, heterogeneous charge attraction action, covalent bond action, physical entanglement action.
10. The method of preparing a voxel printing bio-ink according to any of the claims 7 to 9, wherein the extracellular matrix material comprises a protein fiber material comprising collagen and matrigel; the ultra-long chain biocompatible molecules are crosslinked and solidified with extracellular matrix materials to generate soft spheres, or a plurality of soft spheres are fused into a strip glue after flowing and extruding.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010101998.XA CN111197022A (en) | 2020-02-19 | 2020-02-19 | Voxel printing biological ink and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010101998.XA CN111197022A (en) | 2020-02-19 | 2020-02-19 | Voxel printing biological ink and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111197022A true CN111197022A (en) | 2020-05-26 |
Family
ID=70745203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010101998.XA Pending CN111197022A (en) | 2020-02-19 | 2020-02-19 | Voxel printing biological ink and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111197022A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105885436A (en) * | 2016-04-26 | 2016-08-24 | 中山大学附属第医院 | Biological ink material for 3D printing and preparation method and application thereof |
| CN110180026A (en) * | 2019-06-27 | 2019-08-30 | 清华-伯克利深圳学院筹备办公室 | A kind of biological support and its preparation method and application |
-
2020
- 2020-02-19 CN CN202010101998.XA patent/CN111197022A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105885436A (en) * | 2016-04-26 | 2016-08-24 | 中山大学附属第医院 | Biological ink material for 3D printing and preparation method and application thereof |
| CN110180026A (en) * | 2019-06-27 | 2019-08-30 | 清华-伯克利深圳学院筹备办公室 | A kind of biological support and its preparation method and application |
Non-Patent Citations (3)
| Title |
|---|
| HAO QI 等: "DNA directed self-assembly of shape-controlled hydrogels", 《NAT COMMUN.》 * |
| 胡超然 等: "3D生物打印技术在骨组织工程中的应用", 《中国组织工程研究》 * |
| 马少华 等: "Gel Microrods for 3D Tissue Printing", 《ADV. BIOSYS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Prince et al. | Design and applications of man-made biomimetic fibrillar hydrogels | |
| Rojek et al. | Microfluidic formulation of topological hydrogels for microtissue engineering | |
| Shen et al. | From protein building blocks to functional materials | |
| Zhang et al. | Bioink design for extrusion-based bioprinting | |
| Unagolla et al. | Hydrogel-based 3D bioprinting: A comprehensive review on cell-laden hydrogels, bioink formulations, and future perspectives | |
| Chai et al. | Construction of 3D printed constructs based on microfluidic microgel for bone regeneration | |
| CN108467498B (en) | A kind of chitosan and the supramolecular hydrogel of gelatin and the preparation method and application thereof | |
| Onoe et al. | Cell-laden microfibers for bottom-up tissue engineering | |
| Wan et al. | Fibers by interfacial polyelectrolyte complexation–processes, materials and applications | |
| Guan et al. | PNIPAM microgels for biomedical applications: from dispersed particles to 3D assemblies | |
| CN107041971A (en) | A kind of fibroin based on 3 D-printing/gelatin timbering material and preparation method thereof | |
| CN107636049A (en) | From integration hydrogel and preparation method thereof | |
| CN110402284B (en) | Membrane insertion for a basement membrane scaffold | |
| Liu et al. | Flexible water-absorbing silk-fibroin biomaterial sponges with unique pore structure for tissue engineering | |
| CN100594949C (en) | Method for producing compound frame of injection type polyester micro-carrier and fibrin gel | |
| CN107412877B (en) | Preparation method and application of calcium phosphate/gelatin composite material nanoparticles | |
| CN105504316B (en) | A kind of active ester cross-linking method of hyaluronic acid methylcellulose plural gel | |
| US20070134209A1 (en) | Cellular encapsulation for self-assembly of engineered tissue | |
| CN110124113A (en) | It is orientated conductive collagen hydrogel, bionical conductive Nerve Scaffold material and preparation method thereof | |
| CN105330902A (en) | Hyaluronic acid-methyl cellulose composite hydrogel as well as preparation and application thereof | |
| Chen et al. | Biomaterials for microfluidic technology | |
| Bonani et al. | Alginate hydrogels: a tool for 3D cell encapsulation, tissue engineering, and biofabrication | |
| CN105944143A (en) | Bionic tissue based on acellular matrix-cell-three-dimensional fiber network and preparation method of bionic tissue | |
| Rosellini et al. | Microfluidic Fabrication of Natural Polymer-Based Scaffolds for Tissue Engineering Applications: A Review | |
| CN103819694B (en) | A kind of silk fibroin hydrogel with cell compatibility and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200526 |